Clean Energy Fuels (CLNE) Names Robert Vreeland as CFO Oct 31, 2014 04:11PM

Clean Energy Fuels Corp. (NASDAQ: CLNE) announced today that Robert Vreeland has been appointed Chief Financial Officer effective immediately.

“Bob brings a wealth of financial planning, analytics and accounting experience to the position of CFO as well as having gained a deep knowledge of Clean Energy and the overall natural gas fueling industry over the last few years,” said Andrew J. Littlefair, President and CEO of Clean Energy. “I look forward to partnering with Bob as we keep Clean Energy on the path of continued strong growth with sound financial practices that are taking us closer to profitability.”

Mr. Vreeland served as Vice President of Finance and Accounting at Clean Energy from 2012 to 2014. Before joining Clean Energy, he was a consultant at RV CPA Services, PLLC, a provider of certified public accounting services. From January 1997 to May 2009, Mr. Vreeland held various finance and accounting positions at Hypercom, including Interim CFO; Senior Vice President and Corporate Controller; Senior Vice President, Operations; and Vice President of Financial Planning and Analysis. Prior to joining Hypercom, he spent twelve years at Coopers & Lybrand. Mr. Vreeland earned a B.S. from Northern Arizona University and is a certified public accountant.

Mr. Vreeland is replacing Richard Wheeler who served as Clean Energy’s CFO from 2002 to 2014. Mr. Wheeler resigned his position with Clean Energy effective November 3, 2014 and plans to pursue other interests.

“Rick has been a valuable part of Clean Energy’s rapid growth which has resulted in us becoming the leader in the country’s natural gas vehicle fuel market,” said Mr. Littlefair. “I will miss his sound financial counsel and his ability to make complex transactions seem simple. We wish Rick the very best.”

Biogen Idec (BIIB), Sobi Report EMA Validates ELOCTA MAA for Review Oct 31, 2014 04:08PM

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA™ (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA’s review process.

ELOCTA is the European trade name for rFVIIIFc, which is also known as ELOCTATE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the U.S., Canada, and Australia, where it is approved for the treatment of hemophilia A. ELOCTATE is the first recombinant clotting factor VIII therapy with prolonged circulation to provide protection from bleeding episodes with the potential for an extended interval between prophylactic injections.

“The validation of ELOCTA’s application by the EMA is an important step toward bringing this innovative treatment to people with hemophilia A in Europe,” said Douglas E. Williams, Ph.D., executive vice president of Research and Development at Biogen Idec. “ELOCTA has the potential to protect against bleeding episodes while helping to address the challenge of frequent injections.”

The regulatory application included results from the pivotal, Phase 3 clinical study, A-LONG that examined the efficacy, safety and pharmacokinetics of rFVIIIFc in males 12 years of age and older with severe hemophilia A and from the Phase 3 clinical study, Kids A-LONG that evaluated the efficacy and safety of rFVIIIFc in children with hemophilia A under 12 years of age.

Biogen Idec and Sobi are collaborators in the development and commercialization of ELOCTATE/ELOCTA for hemophilia A. Sobi has an opt-in right to take over final development and commercialization of ELOCTA for the Sobi territories (Europe, North Africa, Russia and most Middle Eastern markets). Biogen Idec leads development for ELOCTATE/ELOCTA, has manufacturing rights, and has commercialization rights in North America and all other regions in the world excluding the Sobi territories.

“Sobi and Biogen Idec are committed to addressing significant medical needs in the global hemophilia community,” said Birgitte Volck, M.D., Ph.D., senior vice president development and chief medical officer of Sobi. “We’re working collaboratively to deliver innovative medicines that have the potential to change the way hemophilia A is treated.”

Westport Innovations (WPRT) Solicitated Kevin Douglas' Views on Strategic Direction - 13D Oct 31, 2014 03:52PM

In a 13D filing on Westport Innovations, Inc. (NASDAQ: WPRT), hedge fund Kevin Douglas disclosed a 15.66%, or 9,848,559 share, stake in the company. This is up 0.54% from the 9,795,657 shares held at the end of the latest quarter ending September 30, 2014.

From the filing:

Representatives of the Issuer recently solicited Kevin Douglas’ views regarding certain matters including the Issuer’s management and strategic direction. The Filers filed this Schedule 13D to permit free communication between the Issuer and Kevin Douglas on this and other topics.

For more notable holders of Westport Innovations, Inc. stock click here.

Sarepta Therapeutics (SRPT) Will Post Q3 Results on Nov. 6th; Street Sees Wider Loss Oct 31, 2014 03:36PM

Sarepta Therapeutics (NASDAQ: SRPT) will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014. Subsequently, at 8:00 a.m. Eastern Time, Chris Garabedian, Sarepta’s president and chief executive officer, and Sandy Mahatme, Sarepta’s chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.

*** The Street is currently looking for Sarepta to post Q3 loss of $0.96 per share with revenue of $3.1 million, from a loss of $0.63 per share and revs of $4.2 million reported in the same period last year.

The conference call may be accessed by dialing 800-708-4539 for domestic callers and 847-619-6396 for international callers. The passcode for the call is 38322454. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2014 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Microsoft (MSFT) Announces New Outlook for Mac Oct 31, 2014 01:53PM

Microsoft (NASDAQ: MSFT) posted the following to its official Office blog on Friday:

Today we are announcing the new Outlook for the Mac, which delivers improved performance and reliability and a fresh look and feel that is unmistakably Microsoft Office. This release offers a more familiar and consistent experience between Outlook on the PC, Outlook on the web and Outlook Web App (OWA) for iPad, iPhone and Android devices.

The new Outlook for Mac includes:

  • Better performance and reliability as a result of a new threading model and database improvements.
  • A new modern user interface with improved scrolling and agility when switching between Ribbon tabs.
  • Online archive support for searching Exchange (online or on-premises) archived mail.
  • Master Category List support and enhancements delivering access to category lists (name and color) and sync between Mac, Windows and OWA clients.
  • Office 365 push email support for real-time email delivery.
  • Faster first-run and email download experience with improved Exchange Web Services syncing.

01 Mail All Retina

The new Outlook for Mac is available to Office 365 commercial customers and Office 365 Home, Office 365 Personal and Office 365 University subscribers.

  • Office 365 Commercial customers can get the new Outlook for Mac by accessing their Office 365 Portal, (Gear icon > Office 365 Settings > Software > Outlook for Mac icon) or visiting the Software page.
  • Office 365 consumer subscribers can get the new Outlook for Mac by going to their My Account page.

For people who already have Office for Mac 2011 and Outlook for Mac 2011 installed on their Mac, check out this help article for guidance.

Microsoft Word, PowerPoint, Excel and OneNote for Mac

Historically we have released a new version of Office for Mac approximately six to eight months after Office for Windows. However, following the release of Office 365 we made the conscious decision to prioritize mobile first and cloud first scenarios for an increasing number of people who are getting things done on-the-go more frequently. This meant delivering and continuing to improve Office on a variety phones (iPhone, Windows Phone, and Android) and tablets (iPad and Windows)—brought together by the cloud (OneDrive) to help people stay better organized and get things done with greater efficiency at work, school, home and everywhere between.

Continuing our commitment to our valued Mac customers, we are pleased to disclose the roadmap for the next version of Office for Mac—including Word for Mac, Excel for Mac, PowerPoint for Mac and OneNote for Mac.

In the first half of 2015 we will release a public beta for the next version of Office for Mac, and in the second half of 2015 we will make the final release available. Office 365 commercial and consumer subscribers will get the next version at no additional cost, and we will release a perpetual license of Office for Mac in the same timeframe.

We’re confident you will like what you see in the new Outlook for Mac today, and in the Office for Mac in the coming months.

To get the best Office 365 email, calendar, contacts and tasks experience on a Mac, download the new Outlook for Mac today, and let us know what you think.

More Corporate News

View Older Stories

Oct 31, 2014 01:51PM PPG Industries (PPG) Reports Favorable Ruling Related to Consorcio Comex Deal
Oct 31, 2014 01:25PM Mesa Laboratories (MLAB) Buys UK, Irish Distributor
Oct 31, 2014 01:14PM FedEx Express (FDX) Seeks NMB Assistance to Expedite Progress of Pilot Negotiations
Oct 31, 2014 01:12PM CTG (CTG) Names Interim CFO, to Resume Buyback
Oct 31, 2014 11:08AM Tribune Publishing Co. (TRUB) Acquires Wrapports Chicago Suburban Publications, No Terms
Oct 31, 2014 09:29AM Level 3 Communications (LVLT) Completes Acquisition of tw telecom (TWTC)
Oct 31, 2014 09:27AM Boeing (BA), Monarch Airlines Announce Finalization of $3.2B+ 737 MAX 8 Order
Oct 31, 2014 09:11AM LiveDeal (LIVE) to Launch Wide-Ranging National Ad Campaign
Oct 31, 2014 08:42AM Zogenix (ZGNX), Purdue Pharma Enter Hydrocodone Product Exclusivity Waivers
Oct 31, 2014 08:33AM SunPower (SPWR) Enters Second JV in China
Oct 31, 2014 08:31AM Orexigen Therapeutics (OREX) Will Make Three Contrave Presentations at 2014 ObesityWeek
Oct 31, 2014 07:29AM Sarepta Therapeutics (SRPT): FDA Expects Eteplirsen Will Qualify for Priority Review
Oct 31, 2014 07:03AM BioLineRx (BLRX) Repors Publication of Encouraging BL-1040 Phase 1/2 Data
Oct 31, 2014 06:26AM Gain Capital (GCAP) to Acquire City Index in Net $82M Deal
Oct 31, 2014 06:07AM Omega Healthcare Investors (OHI) to Acquire Aviv REIT (AVIV) in $3B Deal
Oct 30, 2014 05:46PM Fred's (FRED) Names Jerry A. Shore CEO
Oct 30, 2014 02:25PM Cinedigm (CIDM) Reports Multi-Picture, Multi-Year Deal with Moguldom Studios
Oct 30, 2014 02:10PM Instagram (FB) Video Ads are Officially Rolling Out Nationwide
Oct 30, 2014 01:01PM Bristol-Myers Squibb (BMY), Lonza Expand Manufacturing Pact
Oct 30, 2014 12:19PM GT Advanced Technologies (GTATQ), Apple Lose Bid to Keep Declaration Under Seal - Bloomberg
Oct 30, 2014 09:31AM PDI, Inc. (PDII) Does Not See Digirad's (DRAD) Offer as 'Meaningful'
Oct 30, 2014 09:18AM Blue Earth, Inc. (BBLU) to Acquire Stake in PowerGenix for $10M
Oct 30, 2014 09:15AM Keurig Green Mountain (GMCR), SUPERVALU INC. (SVU) Report Newly Licensed Java Delight Coffee Brand
Oct 30, 2014 09:12AM Ultragenyx Pharmaceutical (RARE) Awarded EU Orphan Drug Designation for KRN23
Oct 30, 2014 09:10AM Bristol-Myers Squibb (BMY) Nivolumab Shows Objective Response Rate of 15% in CheckMate -063 Study
Oct 30, 2014 09:05AM Clean Diesel Technologies (CDTI) Gains After Announcing Two New Patents
Oct 30, 2014 09:02AM Autodesk (ADSK) to Invest $100M in 3D Printing
Oct 30, 2014 08:56AM Chembio Diagn (CEMI) Reports DPP HIV 1/2 Assay Given CLIA Waiver From FDA
Oct 30, 2014 08:51AM Western Gas Partners LP (WES) Prices 7.5M Common Offering at $70.85/Unit
Oct 30, 2014 08:36AM Hemispherx Biopharma (HEB) Reports Evidence Based Potential of Ampligen Against Ebola
Oct 30, 2014 08:34AM Kandi Technologies Group (KNDI) to Launch Car-Share Program in Chengdu; Will Deliver 1,000 Vehicles Before End of 2014
Oct 30, 2014 08:06AM Myos Corporation (MYOS) Reports Data Showing Fortetropin's Anti-Inflammatory Properties
Oct 30, 2014 07:38AM S&T Bancorp (STBA), Integrity Bancshares Enter Merger Pact
Oct 30, 2014 07:17AM Omeros Corp. (OMER) Omidria Receives Pass-Through Status from Center for Medicare & Medicaid Services
Oct 30, 2014 06:52AM GW Pharma (GWPH) Commences Phase 2/3 Trial of Epidiolex
Oct 30, 2014 06:28AM Facebook (FB) Files 162.7M Common Shelf for WhatsApp-Related Shareholders
Oct 30, 2014 06:26AM Apple (AAPL) Smartphone Shipments Rose 16.1% in Q3; Xiaomi Breaks into Top Five - IDC (GOOG) (MSFT)
Oct 29, 2014 05:18PM Novavax (NVAX) H7N9 VLP + Matrix-M Granted FDA Fast-Track Designation
Oct 29, 2014 04:21PM FuelCell Energy (FCEL) to Expand Connecticut Facility
Oct 29, 2014 04:20PM Lakeland Industries (LAKE) Updates on Ebola Efforts; Sees 'Significant' Interest in ChemMAX, MicroMAX Lines
Oct 29, 2014 03:33PM Terex (TEX) Announces Joint Venture with Manitex International
Oct 29, 2014 03:01PM Immunomedics (IMMU) Issues Encouraging Update on IMMU-132
Oct 29, 2014 02:57PM American Realty Capital Properties (ARCP) to Hold Conference Call Today
Oct 29, 2014 02:29PM Lannett (LCI) Letrozole Tabs ANDA Approved by FDA
Oct 29, 2014 02:13PM WI-LAN (WILN) Unit to Acquire Semi Packing IP Portfolio from ROHM Co.
Oct 29, 2014 02:08PM Pfizer (PFE): First Vaccine Approved by FDA to Prevent Serogroup B Meningococcal Disease
Oct 29, 2014 01:43PM Apple (AAPL) in preliminary talks with Iran distributors for the iPhone - WSJ
Oct 29, 2014 01:34PM Bank of America's (BAC) Moynihan Said Mortgage Problems 'Behind Them'
Oct 29, 2014 12:34PM Starboard Sends Letter to RealD (RLD); Urges Reconsideration of Acquisition Proposal
Oct 29, 2014 11:59AM ATK (ATK) to Evaluate Plans on Unit Merger with Orbital (ORB) Following Rocket Disaster
View Older Stories